semaglutide nejm weight loss flow trial 🚨#FLOW: The most anticipated of the year now published in @NEJM with #ERA24 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD Semaglutide in Adults with Type

Wegovy is FDA-approved for chronic weight management

Semaglutide belong to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists which are approved by the FDA for adults with obesity or type 2 diabetes

[1] [2] Persistent or severe symptoms warrant proper clinical evaluation to exclude alternative diagnoses

The purifying method has the advantages of realization of high purity of the prepared semaglutide, substantial improvement of the semaglutide yield, simple operation, and facilitation of realization of large-scale preparation of semaglutide

Untreated sleep issues particularly sleep apnea, which is common in patients with obesity can undermine even the best treatment protocols and may themselves improve meaningfully as weight loss progresses